Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001373604-26-000012·BML Investment Partners, L.P.
Schedule 13G ownership disclosure
Oramed Pharmaceuticals, Inc.
Common Stock par value $0.012 per share · CUSIP: 68403P203
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BML Investment Partners, L.P.
Shares: 3,167,231 · Class: 7.9%
- Leonard Braden Michael
Shares: 3,287,531 · Class: 8.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001373604-26-000012
- Form type
- SCHEDULE 13G/A
- Filer
- BML Investment Partners, L.P.
- CIK
- CIK 1373604
- Filed
- Feb 09, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership